StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) shareholders

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30126% above fair value
$21.89−0.22 (-1.00%)

Close on Nov 18, 2026Market cap $3.69BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
215M of 169M shares
Institutional holders
247
78 new, 22 sold out
Net institutional buying
37M
In Q2 2026
Insider trades, 12 months
0 buys · 30 sales
Net sold $8.08M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
FMR LLC
Joint filing with Abigail P. Johnson (15.00%)
25,286,62415.00%13G (passive) amendmentOct 30, 2026
Linn, Michael G.
Joint filing with Dapice Joshua J. (9.80%), Dreyfuss, Philip D. (9.80%) and 13 more
16,270,1879.80%13G (passive) amendmentJun 30, 2026
TCG Crossover GP II, L.P.
Joint filing with Chen Yu (9.99%), TCG Crossover Fund II, L.P. (9.99%)
13,521,8399.99%13G (passive) amendmentDec 31, 2025
Saito Edric C.
Joint filing with Wehrly, Mark C. (9.99%), Dreyfuss, Philip D. (9.99%) and 13 more
13,461,2159.99%13G (passive) amendmentDec 31, 2025
Roderick Wong
Joint filing with RTW Investments, LP (9.30%)
13,300,6209.30%13G (passive)Mar 31, 2026
TCG Crossover Fund II, L.P.
Joint filing with Chen Yu (8.10%), TCG Crossover GP II, LLC (8.10%)
11,597,7378.10%13G (passive) amendmentMar 31, 2026
Roberts, Jr., Thomas G.
Joint filing with Wehrly, Mark C. (7.80%), Dreyfuss, Philip D. (7.80%) and 13 more
11,257,2037.80%13G (passive) amendmentMar 31, 2026
Giauque, Nicolas
Joint filing with Wehrly, Mark C. (9.70%), Dreyfuss, Philip D. (9.70%) and 15 more
10,757,0009.70%13G (passive) amendmentSep 30, 2025
Davis Aaron I.
Joint filing with Boxer Capital Management, LLC (9.70%)
10,740,38510.00%13D (active) amendmentDec 30, 2024
Robert Atchinson
Joint filing with Adage Capital Management, L.P. (7.88%), Phillip Gross (7.88%)
10,607,9247.88%13G (passive)Dec 31, 2025
TCG Crossover GP II, LLC
Joint filing with Chen Yu (7.00%), TCG Crossover Fund II, L.P. (7.00%)
10,147,8677.00%13G (passive) amendmentJun 30, 2026
Abigail P. Johnson
Joint filing with FMR LLC (6.90%)
9,905,9196.90%13G (passive)Mar 31, 2026
The Goldman Sachs Group, Inc.
Joint filing with Goldman Sachs & Co. LLC (6.00%)
9,742,4036.00%13G (passive)Jun 30, 2026
Trv Gp Iv, LLC
Joint filing with Third Rock Ventures GP IV, L.P. (6.97%), Third Rock Ventures IV, L.P. (6.97%)
9,374,5746.97%13D (active) amendmentNov 12, 2025
Chen Yu
Joint filing with TCG Crossover Fund II, L.P. (6.30%), TCG Crossover GP II, LLC (6.30%)
8,536,1966.30%13G (passive) amendmentSep 30, 2025
BlackRock, Inc.8,477,1656.30%13G (passive)Dec 31, 2025
Aaron I. Davis
Joint filing with Boxer Capital Management, LLC (6.50%)
8,339,9357.80%13D (active) amendmentOct 10, 2024
Costas Constantinides
Joint filing with Ian Charoub (5.10%), Nextech Crossover I GP S.a. r.l. (5.10%) and 2 more
7,266,0815.10%13G (passive) amendmentMar 31, 2026
Dunn Hannah E.
Joint filing with Wehrly, Mark C. (6.60%), Dreyfuss, Philip D. (6.60%) and 15 more
7,182,0006.60%13G (passive)Jun 6, 2025
BCTG Holdings, LLC6,988,4506.50%13D (active) amendmentNov 6, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of TNGXValueChange% of portfolio
Rtw Investments, LP13,900,6208.24%$434.53M+600,0003.71%
BlackRock, Inc.12,438,4447.38%$388.83M+3,690,3990.01%
FMR LLC12,333,3397.31%$385.54M+2,427,4200.02%
Farallon Capital Management LLC12,277,0007.28%$383.78M+3,179,5891.77%
Boxer Capital Management, LLC10,876,2196.45%$339.99M–25.61%
Goldman Sachs Group Inc9,980,6205.92%$311.99M+4,904,2280.03%
TCG Crossover Management, LLC9,081,2015.39%$283.88M−1,449,8706.82%
Trv Gp Iv, LLC6,374,5743.78%$120.18M–47.37%
Paradigm Biocapital Advisors LP6,357,5233.77%$198.74M+2,347,8443.72%
Price T Rowe Associates Inc /Md/6,348,8273.77%$198.47M+5,459,4270.02%
Siren, L.L.C.6,179,3643.66%$193.17M+522,2593.91%
State Street Corp5,979,8063.55%$186.93M+1,327,9120.01%
Vanguard Capital Management LLC5,957,3483.53%$186.23M+795,9170.00%
Adage Capital Partners Gp, L.L.C.5,600,0003.32%$175.06M−7,209,4850.25%
Jupiter Topco LLC5,056,3523.00%$157.99MNew0.06%
Deep Track Capital, LP4,200,0002.49%$131.29M+1,450,0001.91%
Deerfield Management Company, L.P. (Series C)4,190,6112.49%$131.00M+43,7981.37%
Woodline Partners LP4,000,5672.37%$125.06M−3,999,4460.39%
Geode Capital Management, LLC3,742,7912.22%$117.02M+1,067,0140.01%
Perceptive Advisors LLC3,377,0002.00%$105.57M+2,568,8471.58%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026247215M100.0%78 / 10255 / 2268M31M
Q1 2026194180M100.0%59 / 6456 / 3248M33M
Q4 2025170173M100.0%53 / 7527 / 2273M40M
Q3 2025141140M83.0%37 / 4835 / 1027M14M
Q2 2025115127M75.6%21 / 4131 / 2828M8M
Q1 2025122107M63.6%17 / 4338 / 3013M6M
Q4 2024137106M63.1%44 / 4028 / 2741M36M
Q3 2024121102M60.2%18 / 3936 / 1515M8M
Q2 202412099M58.5%20 / 3834 / 254M4M
Q1 202412699M58.6%22 / 3640 / 1612M7M
Q4 202312194M55.7%37 / 4221 / 1614M9M
Q3 202310089M52.7%22 / 3326 / 1122M1M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

211 funds held TNGX in Q2 2026, 46% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of TNGXValue% of fundAs of
Vanguard Total Stock Market Index Fund4,395,7322.61%$137.41M0.01%Jun 30, 2026
iShares Russell 2000 ETF3,607,3452.14%$112.77M0.14%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2,891,0411.71%$90.37M0.84%Jun 30, 2026
Fidelity Growth Company Fund2,472,2001.47%$54.34M0.06%May 31, 2026
Select Biotechnology Portfolio2,339,3621.39%$51.42M0.98%May 31, 2026
T. Rowe Price New Horizons Fund, Inc.1,546,0270.92%$48.33M0.33%Jun 30, 2026
Fidelity Small Cap Index Fund1,539,7560.91%$41.85M0.12%Jul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.1,401,2930.83%$43.80M0.37%Jun 30, 2026
Vanguard Extended Market Index Fund1,365,3300.81%$42.68M0.04%Jun 30, 2026
iShares Russell 2000 Growth ETF1,224,7950.73%$38.29M0.25%Jun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund1,200,5900.71%$37.53M0.38%Jun 30, 2026
Federated Hermes Kaufmann Fund872,5000.52%$23.71M0.48%Jul 31, 2026
Lord Abbett Developing Growth Fund Inc851,1960.50%$23.14M1.04%Jul 31, 2026
Small Cap Growth Fund773,2070.46%$21.02M0.38%Jul 31, 2026
iShares Biotechnology ETF751,4690.45%$23.49M0.26%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Barbara WeberDirector, Executive Chair1,629,5870.97%Feb 4, 2026
Malte PetersPresident & CEO, Director367,5000.22%Jan 12, 2026
Adam CrystalPresident, R&D115,7430.07%Nov 13, 2026
Jessica NewcombPrincipal Accounting Officer52,0900.03%Nov 4, 2026
Matthew GallChief Financial Officer40,0000.02%May 5, 2026
Daniella BeckmanChief Financial Officer184,2970.11%Feb 4, 2026
Douglas BarryGeneral Counsel66,0140.04%Feb 6, 2025
Robert AzelbyDirector5,7400.00%Jun 23, 2026
Lesley Ann CalhounDirector16,5000.01%Jun 8, 2026
John B. KetchumDirector24,9370.01%Jun 8, 2026
Sung LeeDirector22,8700.01%Jun 8, 2026
Mace RothenbergDirector41,5000.02%Jun 8, 2026
Alexis BorisyDirector17,5000.01%Jun 9, 2025
Third Rock Ventures GP IV, L.P.10% owner15,456,8819.17%Oct 27, 2025
Third Rock Ventures IV, L.P.10% owner17,001,47510.08%Oct 27, 2025
Trv Gp Iv, Llc10% owner13,386,5747.94%Oct 27, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Adam Crystal
President, R&D
Nov 11, 2026Sale(10b5-1 plan)−5,000$25.00$125.00K115,743
Adam Crystal
President, R&D
Nov 11, 2026Option exercise+5,000$2.91$14.55K120,743
Adam Crystal
President, R&D
Nov 2, 2026Sale(10b5-1 plan)−1,100$22.99$25.29K115,743
Adam Crystal
President, R&D
Nov 2, 2026Sale(10b5-1 plan)−3,900$22.26$86.82K116,843
Adam Crystal
President, R&D
Nov 2, 2026Option exercise+5,000$2.91$14.55K120,743
Jessica Newcomb
Principal Accounting Officer
Nov 2, 2026Sale(10b5-1 plan)−1,460$22.98$33.55K52,090
Jessica Newcomb
Principal Accounting Officer
Nov 2, 2026Sale(10b5-1 plan)−5,571$22.28$124.11K53,550
Adam Crystal
President, R&D
Oct 1, 2026Sale(10b5-1 plan)−600$25.32$15.19K115,743
Adam Crystal
President, R&D
Oct 1, 2026Sale(10b5-1 plan)−26,400$24.45$645.60K116,343
Adam Crystal
President, R&D
Oct 1, 2026Option exercise+27,000$5.20$140.40K142,743
Jessica Newcomb
Principal Accounting Officer
Sep 22, 2026Sale(10b5-1 plan)−700$22.80$15.96K66,621
Jessica Newcomb
Principal Accounting Officer
Sep 22, 2026Sale(10b5-1 plan)−5,100$23.97$122.25K61,521
Jessica Newcomb
Principal Accounting Officer
Sep 22, 2026Sale(10b5-1 plan)−2,400$25.17$60.41K59,121
Adam Crystal
President, R&D
Sep 1, 2026Option exercise+27,000$5.20$140.40K142,743
Adam Crystal
President, R&D
Sep 1, 2026Sale(10b5-1 plan)−27,000$22.37$603.99K115,743
Adam Crystal
President, R&D
Aug 3, 2026Option exercise+27,000$5.20$140.40K142,743
Adam Crystal
President, R&D
Aug 3, 2026Sale(10b5-1 plan)−5,267$26.79$141.10K137,476
Adam Crystal
President, R&D
Aug 3, 2026Sale(10b5-1 plan)−21,733$27.35$594.40K115,743
Adam Crystal
President, R&D
Jul 1, 2026Sale(10b5-1 plan)−19,629$29.34$575.91K123,114
Adam Crystal
President, R&D
Jul 1, 2026Sale(10b5-1 plan)−7,371$30.25$222.97K115,743
Adam Crystal
President, R&D
Jul 1, 2026Option exercise+27,000$5.20$140.40K142,743
Robert Azelby
Director
Jun 19, 2026Award+5,740––5,740
Mace Rothenberg
Director
Jun 5, 2026Award+4,000––41,500
Sung Lee
Director
Jun 5, 2026Award+570––22,870
John B. Ketchum
Director
Jun 5, 2026Award+4,000––24,937
Lesley Ann Calhoun
Director
Jun 5, 2026Award+4,000––16,500
Adam Crystal
President, R&D
Jun 1, 2026Sale(10b5-1 plan)−6,140$22.25$136.62K136,603
Adam Crystal
President, R&D
Jun 1, 2026Sale(10b5-1 plan)−20,860$23.06$481.03K115,743
Adam Crystal
President, R&D
Jun 1, 2026Option exercise+27,000$5.20$140.40K142,743
Matthew Gall
Chief Financial Officer
May 1, 2026Award+40,000––40,000
Adam Crystal
President, R&D
May 1, 2026Sale(10b5-1 plan)−1,100$22.00$24.20K115,743
Adam Crystal
President, R&D
May 1, 2026Option exercise+27,000$5.20$140.40K142,743
Adam Crystal
President, R&D
May 1, 2026Sale(10b5-1 plan)−25,900$21.19$548.82K116,843
Sung Lee
Director
Apr 29, 2026Award+12,300––22,300
Adam Crystal
President, R&D
Apr 15, 2026Sale(10b5-1 plan)−38,460$25.00$961.50K112,622
Adam Crystal
President, R&D
Apr 15, 2026Option exercise+38,460$5.20$199.99K151,082
Adam Crystal
President, R&D
Apr 1, 2026Option exercise+27,000$5.20$140.40K139,622
Adam Crystal
President, R&D
Apr 1, 2026Sale(10b5-1 plan)−27,000$21.20$572.40K112,622
Adam Crystal
President, R&D
Mar 25, 2026Sale(10b5-1 plan)−12,000$20.11$241.32K112,622
Adam Crystal
President, R&D
Mar 25, 2026Option exercise+12,000$5.20$62.40K124,622
Adam Crystal
President, R&D
Mar 5, 2026Sale(10b5-1 plan)−20,251$15.00$303.77K112,622
Adam Crystal
President, R&D
Feb 25, 2026Sale(10b5-1 plan)−54,345$12.77$693.99K132,873
Barbara Weber
Director, Executive Chair
Feb 3, 2026Sale−30,186$12.26$370.08K1,629,587
Barbara Weber
Director, Executive Chair
Feb 3, 2026Sale−333$12.90$4.30K1,629,254
Daniella Beckman
Chief Financial Officer
Feb 3, 2026Sale−113$12.90$1.46K184,297
Daniella Beckman
Chief Financial Officer
Feb 3, 2026Sale−10,204$12.26$125.10K184,410
Adam Crystal
President, R&D
Feb 3, 2026Sale−18,251$12.26$223.76K187,419
Adam Crystal
President, R&D
Feb 3, 2026Sale−201$12.90$2.59K187,218
Barbara Weber
Director, Executive Chair
Feb 2, 2026Award+37,522––1,659,773
Daniella Beckman
Chief Financial Officer
Feb 2, 2026Award+44,330––194,614
Adam Crystal
President, R&D
Feb 2, 2026Award+47,460––205,670
Malte Peters
President & CEO, Director
Jan 8, 2026Award+350,000––367,500
Sung Lee
Director
Jan 2, 2026Award+10,000––10,000
Trv Gp Iv, Llc
10% owner
Oct 23, 2025Sale−477,401$10.15$4.85M13,386,574
Trv Gp Iv, Llc
10% owner
Sep 25, 2025Sale−500,000$8.02$4.01M13,863,975
Trv Gp Iv, Llc
10% owner
Sep 16, 2025Sale−363,541$7.04$2.56M14,363,975
Trv Gp Iv, Llc
10% owner
Sep 8, 2025Sale−86,459$7.04$608.67K14,727,516
Trv Gp Iv, Llc
10% owner
Sep 5, 2025Sale−642,906$7.00$4.50M14,813,975
Third Rock Ventures GP IV, L.P.
10% owner
Aug 22, 2025Sale−302,194$7.00$2.12M15,456,881
Third Rock Ventures GP IV, L.P.
10% owner
Aug 19, 2025Sale−1,100,000$7.01$7.71M15,759,075

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
32.39%
48M shares short
Days to cover
9.7
At 5M shares a day
Change since last report
+7.7%
From 45M shares
Short volume, 20 days
53.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Tango Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 491,105 shares on Sep 24, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Adam Crystal
Officer
Nov 2, 202620,000$454.40KNov 2, 2026Exercise of Stock Options
Jessica Newcomb
Officer
Sep 22, 202615,231$340.11KSep 22, 2026Restricted Stock Units
Adam Crystal
Officer
Aug 3, 202681,000$2.20MAug 3, 2026Exercise of Stock Options
Nextech Crossover I SCSp
Former Affiliate
Jun 17, 20263,766,081$113.36MJun 17, 2026Private Placement
Daniella Beckman
Officer
Jun 11, 20261,791,726$51.52MJun 11, 2026Stock Option Exercise
Daniella Beckman
Officer
Jun 10, 20264,446$133.38KJun 10, 2026Stock Option Exercise
Adam Crystal
Officer
May 1, 202665,460$1.42MMay 1, 2026Exercise of Stock Options
Adam Crystal
Officer
Mar 25, 202693,000$1.81MMar 25, 2026Exercise of Stock Options
Adam Crystal
Officer
Mar 5, 202620,251$250.10KMar 5, 2026Exercise of Stock Options
Adam Crystal
Officer
Feb 25, 202654,345$699.96KFeb 25, 2026Restricted Stock Units
Third Rock Ventures IV, L.P.
10% Stockholder
Oct 23, 2025477,401$3.59MOct 23, 2025Pre-IPO investment
Third Rock Ventures IV, L.P.
10% Stockholder
Sep 25, 2025500,000$3.90MSep 25, 2025Pre-IPO investment
Third Rock Ventures IV, L.P.
10% Stockholder
Sep 17, 2025363,541$2.67MSep 16, 2025Pre-IPO investment
Third Rock Ventures IV, L.P.
10% Stockholder
Sep 8, 202586,459$608.63KSep 8, 2025Pre-IPO investment
Third Rock Ventures IV, L.P.
10% Stockholder
Sep 5, 2025642,906$4.46MSep 5, 2025Pre-IPO investment

See a number that looks wrong?